Patents by Inventor Robert McKay

Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6448079
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: September 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay
  • Publication number: 20020103628
    Abstract: An embodiment of the invention is a method for performing thermal feasibility analysis for an enclosure containing electronics. The method includes obtaining design parameters related to the enclosure. A thermal feasibility analysis is performed for a plurality of enclosure designs in response to the design parameters. The enclosure designs vary in enclosure material, mounting location of the electronics and presence of a heat sink. The results of the thermal feasibility analysis are displayed for the plurality of enclosure designs.
    Type: Application
    Filed: August 23, 2001
    Publication date: August 1, 2002
    Inventors: Scott J. Leslie, Robert McKay
  • Publication number: 20020058638
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases and conditions associated with expression of PTEN are provided. Such conditions include diabetes and hyperproliferative conditions. Methods for decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels in an animal using the compounds of the invention are also provided. The animal is preferably a human; also preferably the animal is a diabetic animal.
    Type: Application
    Filed: June 11, 2001
    Publication date: May 16, 2002
    Inventors: Brett P. Monia, Lex M. Cowsert, Robert McKay
  • Publication number: 20020055479
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: May 14, 2001
    Publication date: May 9, 2002
    Inventors: Lex M. Cowsert, Jacqueline Wyatt, Susan M. Freier, Brett P. Monia, Madeline M. Butler, Robert McKay
  • Publication number: 20020049173
    Abstract: The present invention provides compositions and methods for controlling the behavior of a cell, tissue or organism through antisense modulation of mRNA processing, using antisense compounds which does not support cleavage of the mRNA target.
    Type: Application
    Filed: December 12, 2000
    Publication date: April 25, 2002
    Inventors: C. Frank Bennett, Stanley T. Crooke, Muthiah Manoharan, Jacqueline Wyatt, Brenda F. Baker, Brett P. Monia, Robert McKay, James G. Karras
  • Publication number: 20020039741
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of Activating Protein 1 (AP-1) expression are provided. In accordance with various embodiments of the present invention, oligonucleotides are provided which are specifically hybridizable with c-fos or c-jun, the genes encoding c-Fos or c-Jun, respectively. In a preferred embodiment, a method of modulating the metastasis of malignant tumors via modulation of one or more of the AP-1 subunits is provided; this method can be effected using the oligonucleotides of the invention or any other agent which modulates AP-1 or AP-1 mediated transcription.
    Type: Application
    Filed: August 7, 2001
    Publication date: April 4, 2002
    Inventors: Nicholas M. Dean, Robert McKay, Loren Miraglia, Brenda Baker
  • Patent number: 6323029
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: November 27, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Madeline M. Butler, Robert McKay, Brett P. Monia, Jacqueline Wyatt
  • Patent number: 6316259
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 alpha. Methods of using these compounds for modulation of glycogen synthase kinase 3 alpha expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 alpha are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: November 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Robert McKay, Madeline M. Butler, Jacqueline Wyatt
  • Patent number: 6312900
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of Activating Protein 1 (AP-1) expression are provided. In accordance with various embodiments of the present invention, oligonucleotides are provided which are specifically hybridizable with c-fos or c-jun, the genes encoding c-Fos or c-Jun, respectively. In a preferred embodiment, a method of modulating the metastasis of malignant tumors via modulation of one or more of the AP-1 subunits is provided; this method can be effected using the oligonucleotides of the invention or any other agent which modulates AP-1 or AP-1-mediated transcription.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: November 6, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Robert McKay, Loren Miraglia, Brenda Baker
  • Patent number: 6300320
    Abstract: Methods and compositions are provided for modulating c-jun expression using inhibitors of PKC-&agr;. In preferred embodiments, the specific inhibitors are antisense oligonucleotides hybridizable to PKC-&agr;. In preferred embodiments, the oligonucleotides contain one or more chemical modifications.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: October 9, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Robert McKay
  • Patent number: 6284538
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases and conditions associated with expression of PTEN are provided. Such conditions include diabetes and hyperproliferative conditions. Methods for decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels in an animal using the compounds of the invention are also provided. The animal is preferably a human; also preferably the animal is a diabetic animal.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: September 4, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Robert McKay
  • Patent number: 6221850
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. The invention is thus directed to compositions for modulating, diagnostic methods for detecting, and therapeutic methods for inhibiting, the hyperproliferation of cells and formation, development and maintenance of tumors.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: April 24, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela Scott Nero, William A. Gaarde
  • Patent number: 6210892
    Abstract: The present invention provides compositions and methods for controlling the behavior of a cell, tissue or organism through antisense modulation of mRNA processing, using antisense compounds which does not support cleavage of the mRNA target.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: April 3, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Stanley T. Cooke, Muthiah Manoharan, Jacqueline R. Wyatt, Brenda F. Baker, Brett P. Monia, Susan M. Freier, Robert McKay, James G. Karras
  • Patent number: 6187545
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-cytosolic. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-cytosolic. Methods of using these compounds for modulation of PEPCK-cytosolic expression and for treatment of diseases associated with expression of PEPCK-cytosolic are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Jacqueline Wyatt, Lex M. Cowsert
  • Patent number: 6159734
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Peroxisome proliferator-activated receptor gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Peroxisome proliferator-activated receptor gamma. Methods of using these compounds for modulation of Peroxisome proliferator-activated receptor gamma expression and for treatment of diseases associated with expression of Peroxisome proliferator-activated receptor gamma are provided.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: December 12, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Robert McKay, Alexander H. Borchers, Brenda F. Baker
  • Patent number: 6140124
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero, Robert McKay
  • Patent number: 6136603
    Abstract: Compositions and methods are provided for antisense modulation of interleukin-5 signal transduction. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding interleukin-5 and interleukin-5 receptor.alpha. are preferred. Methods of using these compounds for modulation of interleukin-5 signal transduction and for treatment of diseases associated with interleukin-5 signal transduction are also provided.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: October 24, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, James G. Karras, Robert McKay
  • Patent number: 6133246
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: October 17, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela S. Nero, William A. Gaarde
  • Patent number: 6030837
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-mitochondrial. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-mitochondrial. Methods of using these compounds for modulation of PEPCK-mitochondrial expression and for treatment of diseases associated with expression of PEPCK-mitochondrial are provided.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: February 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Lex M. Cowsert
  • Patent number: 5985558
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of Activating Protein 1 (AP-1) expression are provided. In accordance with various embodiments of the present invention, oligonucleotides are provided which are specifically hybridizable with c-fos or c-jun, the genes encoding c-Fos or c-Jun, respectively. In a preferred embodiment, a method of modulating the metastasis of malignant tumors via modulation of one or more of the AP-1 subunits is provided; this method can be effected using the oligonucleotides of the invention or any other agent which modulates AP-1 or AP-1-mediated transcription.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: November 16, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, Robert McKay, Loren Miraglia, Brenda Baker